`571.272.7822
`
`
`
`
`
`
`
`
`
`
` Paper No. 12
`
` Entered: October 23, 2017
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`ARAGEN BIOSCIENCE, INC.
`AND
`TRANSPOSAGEN BIOPHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`KYOWA HAKKO KIRIN CO., LTD.,
`Patent Owner.
`____________
`
`Case IPR2017-01262
`Patent 7,425,446 B2
`____________
`
`
`Before JAMES T. MOORE, ERICA A. FRANKLIN, and
`ROBERT A. POLLOCK, Administrative Patent Judges.
`
`MOORE, Administrative Patent Judge.
`
`
`
`DECISION
`Denying Institution of Inter Partes Review
`37 C.F.R. § 42.108
`
`
`
`
`
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`
`
`INTRODUCTION
`
`Aragen Bioscience, Inc. and Transposagen Biopharmaceuticals, Inc.
`
`(collectively “Petitioner”)1 filed a Petition requesting an inter partes review
`
`of claims 1–6 of U.S. Patent No. 7,425,446 B2 (Ex. 1001, “the ’446
`
`Patent”). Paper 1 (“Pet.”). Kyowa Hakko Kirin Co., Ltd. (“Patent Owner”)
`
`filed a Preliminary Response to the Petition. Paper 8 (“Prelim. Resp.”).
`
`Institution of an inter partes review is authorized by statute when “the
`
`information presented in the petition . . . and any response . . . shows that
`
`there is a reasonable likelihood that the petitioner would prevail with respect
`
`to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314; see
`
`37 C.F.R. §§ 42.4, 42.108. Upon considering the Petition and the
`
`Preliminary Response, we determine that Petitioner has not shown a
`
`reasonable likelihood that it would prevail in showing the unpatentability of
`
`at least one challenged claim. Accordingly, we decline to institute an inter
`
`partes review of the ’446 Patent.
`
`A.
`
`Related Proceedings
`
`Petitioner has submitted additional Petitions challenging claims of
`
`U.S. Patent 8,067,232 B2 (IPR2017-01254), and U.S. Patent 6,946,292 B2
`
`(IPR2017-01252), which have similar specifications.
`
`According to the parties, the ’446 Patent is also at issue in Kyowa
`
`Hakko Kirin Co. v. Aragen Bioscience, Inc., Case No. 3-16-cv-05993-JD
`
`(N.D. Cal.) (“the copending district court litigation”). Pet. 59.
`
`
`
`
`
`1 Petitioner further identifies GVK Biosciences, Private Limited and GVK
`Davix Technologies Private Limited as real parties-in-interest. Pet. 59.
`
`2
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`B.
`
`The ’446 Patent
`
`The ’446 Patent, titled “Antibody Composition-Producing Cell”
`
`relates to a cell for the production of an antibody molecule such as an
`
`antibody useful for various diseases having high antibody-dependent cell-
`
`mediated cytotoxic activity (“ADCC”), a fragment of the antibody and a
`
`fusion protein including a region of the antibody. The Patent also relates to
`
`a method for producing an antibody composition using the cell, the antibody
`
`composition itself, and the use thereof. Ex. 1001, Abstract.
`
`The antibody molecule is produced in part by altering the
`
`fucosyltransferase 8 (FUT8) gene of a host cell involved in the production of
`
`α1,6-fucosyltransferase which disrupts its expression and changes the
`
`antibody by limiting fucose attachment. Ex. 1001, claim 1.
`
`ADCC is an inflammatory response mediated by natural killer (“NK”)
`
`cells that can result in the killing of tumor cells. See Pet. 3–4 (citing
`
`Ex. 10262 ¶¶ 22–25). In ADCC, the fragment crystallizable (“Fc”) portions
`
`of immunoglobulin G (“IgG”) -type antibodies decorating a target cell (e.g.,
`
`a tumor cell) are recognized by Fc receptors (e.g., FcγRIII or CD163) on the
`
`NK cell surface. Id. The interaction between target cell-specific antibodies
`
`and Fc receptors activates the NK cell, which then kills the target cell. Id.
`
`24.
`
`According to the instant Specification, the hinge region and the
`
`second domain of the constant region (“Cγ2 domain”) of the antibody are
`
`
`
`2 Declaration of Dr. Royston Jefferis. At this time we find that, based upon
`his credentials and experience, Dr. Jefferis is qualified to testify to this
`subject matter. Ex. 1026, ¶¶ 4–6 and Exhibit B thereto.
`3 A class of low-affinity Fc receptors found on the surface of NK cells.
`
`3
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`important to this binding, and thus ADCC activity expression. The same is
`
`said for the sugar chain binding to the Cγ2 domain. Ex. 1001, 1:64–2:10.
`
`The ’446 Patent states that, despite efforts to investigate the effects of
`
`altering the antibody, “it cannot be said that an actual important structure for
`
`the effector [f]unction was identified” Id. 2:36–37.
`
`Also according to the Specification, high ADCC activity is found
`
`when the ratio of antibodies having fucose that is not bound to
`
`N-acetylglucosamine in the reducing end of the sugar chain is raised relative
`
`to antibodies having fucose bound there. Id. 20:46:59. This is the alteration
`
`of the antibody caused by manipulation of the FUT8 gene.
`
`The Specification discloses the design and testing of a mammalian
`
`host cell line for producing antibodies where the FUT8 gene—the gene
`
`encoding α1,6-fucosyltransferase—was enhanced (Example 11) and
`
`disrupted (Examples 12, 13), thereby either over-expressing or reducing (or
`
`eliminating) α1,6-fucosyltransferase activity and thus the binding of fucose
`
`into the sugar chain. Id. 89:10–111:47. In short, a deletion in the α1,6-
`
`fucosyltransferase gene of mammalian cells produced more potent cells.
`
`Specifically, the “ADCC activity of produced antibodies can be improved by
`
`disrupting the FUT8 allele in host cells,” Id. 111:45–46.
`
`C.
`
`Representative Claim
`
`Claim 1, the sole dependent claim, recites,
`
`1. An isolated mammalian host cell which has decreased or no
`α1,6-fucosyltransferase activity for adding fucose
`to N-
`acetylglucosamine of a reducing terminus of N-glycoside-linked
`sugar chains by deleting a gene encoding α1,6-fucosyltransferase
`or by adding a mutation to said gene to reduce or eliminate the
`α1,6-fucosyltransferase activity, wherein said mammalian host
`cell produces an antibody molecule.
`
`4
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`Ex. 1001, 183:30–37.
`
`Depending from claim 1, claims 2–5 are each limited to a host cell
`
`types CHO (Chinese hamster ovary), NSO (a mouse myeloma cell), SP 2/0
`
`(another mouse myeloma cell), and YB 2/0 (a rat myeloma cell),
`
`respectively. Id., 183:37–38 and 184:29-34. Also depending from claim 1,
`
`claim 6 recites that the antibody molecule is an IgG antibody. Id., 184:34-
`
`36.
`
`D.
`
`The Asserted Prior art and Grounds of Unpatentability
`
`Petitioner asserts the following grounds of unpatentability (Pet. 17):
`
`Ground Reference(s)
`
`Basis
`
` Claims
`
`1
`
`2
`
`3
`
`4
`
`Rothman,4 Umaña,5 knowledge
`of a person of ordinary skill in
`the art (“POSA”)
`Harris,6 Umaña, knowledge of
`POSA
`
`Rothman, Umaña, Malý,7
`knowledge of POSA
`
`Harris, Umaña, Malý,
`knowledge of POSA
`
`§ 103
`
` 1–6
`
`§ 103
`
`1–6
`
`§ 103
`
`1–6
`
`§ 103
`
`1–6
`
`
`
`4 Rothman et al., Antibody-dependent cytotoxicity mediated by natural killer
`cells is enhanced by castonspermine-induced alterations of IgG
`glycosylation, 26(12) MOLEC. IMMUNOL. 1113–23 (1989). Ex. 1002.
`5 WO 99/54342, published Oct. 28, 1999. Ex. 1004.
`6 Harris et al., Refined structure of an intact IgG2a monoclonal antibody, 36
`Biochemistry 1581–97 (1997). Ex. 1003.
`7 Malý et al., The α(1,3)fucosyltransferase Fuc-TVII controls leukocyte
`trafficking through an essential role in L-, E-, and P-selectin ligand
`biosynthesis, 86 CELL 643–53 (1996). Ex. 1005.
`
`5
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`Ground Reference(s)
`
`Basis
`
` Claims
`
`5
`
`6
`
`Rothman, Umaña, Gao,8
`knowledge of POSA
`
`Harris, Umaña, Gao,
`knowledge of POSA
`
`§ 103
`
`§ 103
`
`5
`
`5
`
`Petitioner also relies on the Declarations of Dr. Brian G. Van Ness
`
`(Ex. 1007)9 and Dr. Royston Jefferis (Ex. 1026). Petitioner further relies on
`
`the June 22, 2017, transcript of the deposition testimony of Dr. Brian
`
`Van Ness taken in the copending district court litigation (Exhibit 1038), and
`
`a supplemental paper relating to that testimony (Paper 11), both of which
`
`were entered in this case subject to the Board’s Order of August 9, 2017
`
`(Paper 10).
`
`E. Overview of the Asserted References
`
`i. Rothman (Ex. 1002)
`
`Rothman describes the functional analysis of monoclonal IgG
`
`antibodies (“mAbs”) produced in culture in the presence of various
`
`glycosylation inhibitors. See, e.g., Ex. 1002, Abstract, 1121.10 Rothman
`
`reports that, although oligosaccharide modification did not significantly
`
`influence antigen binding to target cells, “a correlation was observed
`
`between the efficiency of promoting ADCC and the glycosylation phenotype
`
`of the mAb.” Id. at 1121. In particular, ADCC was enhanced when the IgG
`
`
`
`8 Gao et al., Characterization of YB2/0 cell line by counterflow
`centrifugation elutriation, 44 Exp. Toxic. Pathol. 435–38 (1992). Ex. 1006.
`9 We find Dr. Van Ness to be qualified to testify to the subject matter of this
`proceedings by virtue of his education and experience. Ex. 1007 ¶¶ 4–12
`and Exhibit B thereto.
`10 Where possible, we refer to the native page numbers of the exhibits.
`
`6
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`oligosaccharides were metabolically modified by exposure to
`
`castanospermine (Cs) and certain other inhibitors. See, e.g., id at Abstract,
`
`1121.
`
`Rothman suggests that “absence of core fucosylation itself would
`
`appear to be a likely candidate as a structural feature necessary for
`
`enhancement of NK cell-mediated ADCC.” Id. at 1122. Further “it is
`
`tempting to speculate that polyclonal variability in the expression of core
`
`fucosylation may confer a functional advantage to host defense by
`
`diversifying the effector activity of IgG.” Id. We are not provided with
`
`evidence or argument that Rothman itself describes a gene encoding
`
`mammalian α1,6-fucosyltransferase.
`
`ii. Harris (Ex. 1003)
`
`Harris describes the crystal structure (including oligosaccharide
`
`components) of an IgG-type monoclonal antibody directed against a canine
`
`lymphoma. See Ex. 1003, Abstract, 1590–92. In comparing the Fc region
`
`of the canine antibody against that of a human antibody, Harris states that,
`
`the principal differences lie in the orientation and placement of
`Fuc2 and of the branch ends Gal7 and Nag9 (Figure 10).11 The
`fucose residue may be of particular interest. In both this
`antibody and the human Fc it interacts with Tyr313 [of the IgG
`heavy chain], but the interactions are quite different in the two
`cases. This fucose is also near the Fcγ receptor binding site and
`could influence binding by the receptor.
`
`Id. 1592.
`
`With respect to effector function, Harris further states:
`
`
`
`11 We understand Fuc2, Gal7, and Nag9 to refer to specifically numbered
`sugar moieties (fucose, galactose, and N-acetyl glucosamine, respectively)
`of the IgG oligosaccharide chains.
`
`7
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`No direct evidence, that we know of, suggests that the
`oligosaccharides form part of any effector binding site.
`Degradation or modification of the carbohydrate has, however,
`been clearly shown to eliminate or reduce effector functions
`such as . . . binding to Fc receptors . . . .
`
`Id. at 1593–94. Again, we are not provided evidence or argument that
`
`Harris itself describes a gene encoding mammalian α1,6-fucosyltransferase.
`
`iii. Umaña (Ex. 1004)
`
`Umaña is directed to the production of antibodies and other proteins
`
`having altered glycosylation patterns that provide improved therapeutic
`
`properties. Ex. 1004, Abstract, 2.
`
`In particular, Umaña states that:
`
`More specifically, the present invention is directed to a method
`for producing altered glycoforms of proteins having improved
`therapeutic values, e.g., an antibody which has an enhanced
`antibody dependent cellular cytotoxicity (ADCC), in a host cell.
`The invention provides host cells which harbor a nucleic acid
`encoding the protein of interest, e.g., an antibody, and at least
`one nucleic acid encoding a glycoprotein-modifying glycosyl
`transferase.
`
`Id. 3:6–11. Among the techniques taught by Umaña, are “the use of gene
`
`knockout technologies . . . to tailor the host cell’s glycosyl transferase and/or
`
`glycosidase expression levels.” Id. 15:20–22. As above, we are not
`
`provided evidence or argument that Umaña itself describes a gene encoding
`
`mammalian α1,6-fucosyltransferase.
`
`iv. Malý (Ex. 1005)
`
`According to Malý, five genes Fucosyltransferase VII (“Fuc-TVII”),
`
`Fucosyltransferase III (“Fuc-TIII”), Fucosyltransferase V (“Fuc-TV”),
`
`Fucosyltransferase VI (“Fuc-TVI”), and Fucosyltransferase IV (“Fuc-TIV”)
`
`encode α(1,3)fucosyltransferases in humans. Ex. 1005, 649; see id. 643.
`
`8
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`Malý discloses the targeted disruption of the mouse homolog of Fuc-TVII,
`
`and the generation of mice homozygous for the knockout of this gene.
`
`Ex. 1005, 644.
`
`According to Malý, “mice deficient in α(1,3)fucosyltransferase Fuc-
`
`TVII exhibit a leukocyte adhesion deficiency characterized by absent
`
`leukocyte E- and P-selectin ligand activity and deficient HEV12 L-selectin
`
`ligand activity.” Id., Abstract (Footnote added). Malý indicates that “Fuc-
`
`TVII decorates the oligosaccharide components of these glycoproteins with
`
`α(1,3)fucose residues essential to effective E- and P-selectin ligand activity.”
`
`Id. at 649. As with the other references, we are not provided evidence or
`
`argument that Malý itself describes a gene encoding mammalian α1,6-
`
`fucosyltransferase.
`
`v. Gao (Ex. 1006)
`
`Gao describes the separation of YB2/0 cells into cell fractions
`
`according to cell cycle stages using counterflow centrifugal elutriation.
`
`Ex. 1006, 435. According to Gao, “[t]he YB2/0 plasmacytoma cell line is a
`
`highly efficient partner for the production of hybridomas.” Id. 437. We are
`
`not provided evidence or argument that Gao itself describes a gene encoding
`
`mammalian α1,6-fucosyltransferase.
`
`
`
`ANALYSIS
`
`a.
`
`Principles of Law
`
`A claim is unpatentable under 35 U.S.C. § 103(a) if the differences
`
`between the subject matter sought to be patented and the prior art are such
`
`
`
`12 Short for high endothelial venules, cells which express specific adhesion
`molecules such as this ligand.
`
`9
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`that the subject matter as a whole would have been obvious at the time the
`
`invention was made to a person having ordinary skill in the art to which that
`
`subject matter pertains. KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 406
`
`(2007).
`
`The question of obviousness is resolved based on underlying factual
`
`determinations including: (1) the scope and content of the prior art; (2) any
`
`differences between the claimed subject matter and the prior art; (3) the level
`
`of ordinary skill in the art; and (4) objective evidence of nonobviousness, if
`
`present. Graham v. John Deere Co., 383 U.S. 1, 17–18 (1966). Although
`
`the KSR test is flexible, we “must still be careful not to allow hindsight
`
`reconstruction of references . . . without any explanation as to how or why
`
`the references would be combined to produce the claimed invention.”
`
`TriVascular, Inc. v. Samuels, 812 F.3d 1056, 1066 (Fed. Cir. 2016) (citation
`
`omitted).
`
`“In an [inter partes review], the petitioner has the burden from the
`
`onset to show with particularity why the patent it challenges is
`
`unpatentable.” Harmonic Inc. v. Avid Tech., Inc., 815 F.3d 1356, 1363 (Fed.
`
`Cir. 2016) (citing 35 U.S.C. § 312(a)(3) (requiring inter partes review
`
`petitions to identify “with particularity . . . the evidence that supports the
`
`grounds for the challenge to each claim”)).
`
`This burden of persuasion never shifts to Patent Owner. See Dynamic
`
`Drinkware, LLC v. Nat’l Graphics, Inc., 800 F.3d 1375, 1378 (Fed. Cir.
`
`2015) (discussing the burden of proof in inter partes review). “To satisfy its
`
`burden of proving obviousness, a petitioner cannot employ mere conclusory
`
`statements. The petitioner must instead articulate specific reasoning, based
`
`on evidence of record, to support the legal conclusion of obviousness.” In re
`
`10
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`Magnum Oil Tools Int’l, Ltd., 829 F.3d 1364, 1380 (Fed. Cir. 2016) (citing
`
`KSR, 550 U.S. at 418).
`
`We analyze the challenges presented in the Petition in accordance
`
`with the above-stated principles.
`
`A.
`
`Claim Construction
`
`In an inter partes review, claim terms in an unexpired patent are
`
`interpreted according to their broadest reasonable construction in light of the
`
`specification of the patent in which they appear. 37 C.F.R. § 42.100(b);
`
`Cuozzo Speed Techs., LLC v. Lee, 136 S. Ct. 2131, 2144–46 (2016)
`
`(upholding the use of the broadest reasonable interpretation standard).
`
`Under that standard, we presume that a claim term carries its “ordinary and
`
`customary meaning,” which “is the meaning that the term would have to a
`
`person of ordinary skill in the art in question” at the time of the invention.
`
`In re Translogic Tech., Inc., 504 F.3d 1249, 1257 (Fed. Cir. 2007) (citation
`
`omitted).
`
`Petitioner proposes that the term “which has decreased or no α-1,6-
`
`fucosyltransferase activity for adding fucose” of the challenged claims
`
`should mean “which has zero or no α-1,6-fucosyltransferase activity for
`
`adding fucose.” Pet. 17. Petitioner also proposes that the term “deleting a
`
`gene encoding α-1,6-fucosyltransferase or by adding a mutation to said gene
`
`to reduce or eliminate the α-1,6-fucosyltranferase activity” should be
`
`interpreted to mean “deleting a gene encoding α-1,6-fucosyltransferase or by
`
`adding a mutation to said gene to remove or eliminate the α-1,6-
`
`fucosyltranferase activity.” Id.
`
`The rationale behind this interpretation is that the claim is not enabled
`
`for a mere decrease in activity as the ‘knock out’ of the gene eliminates the
`
`11
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`activity entirely. Id, 17–20. Petitioner relies upon prosecution history of the
`
`grandparent application wherein the Examiner rejected claims as lacking
`
`enablement as support for this position.
`
`We are not persuaded by this position. Whatever the scope of the
`
`claims might be, we will not intentionally read them in a manner contrary to
`
`their express language in order to exclude subject matter which might not
`
`have been enabled in a previous application.
`
`Patent Owner asserts that no construction is required at this time.
`
`Prelim. Resp. 20. At this stage of the proceeding, we agree with Patent
`
`Owner, and find that no explicit construction of any claim term is necessary
`
`to determine whether to institute a trial in this case. See Wellman, Inc. v.
`
`Eastman Chem. Co., 642 F.3d 1355, 1361 (Fed. Cir. 2011) (“[C]laim terms
`
`need only be construed ‘to the extent necessary to resolve the controversy.’”
`
`(quoting Vivid Techs., Inc. v. Am. Sci. & Eng’g, Inc., 200 F.3d 795, 803
`
`(Fed. Cir. 1999))).
`
`
`
`B.
`
`Person of Ordinary Skill in the Art.
`
`According to Petitioner, one of ordinary skill in the art on October 6,
`
`2000 (the earliest possible filing date of the invention) would have had
`
`“knowledge of the scientific literature . . . concerning the means and
`
`methods for creating cells in which the gene for the fucose-adding enzyme
`
`fucosyltransferase was knocked out, resulting in a modified sugar chain
`
`giving improved antibodies.” Pet. 16 (citing Ex. 1026 ¶¶ 12–14; Ex. 1007 ¶¶
`
`18–20). The hypothetical person of ordinary skill in the art would have also
`
`had “a doctorate in molecular immunology or biochemistry of glycoproteins
`
`including antibodies, knowledge of routine genetic procedures including
`
`12
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`gene ‘knock-outs,’ and a few years’ practical experience working on the
`
`genetics of antibodies.” Id. Petitioner further directs us to the level of skill
`
`in the art indicated by Applicants during prosecution. Id. (citing Ex. 1036-
`
`B, Aug 12, 2004 Amendment at 32–35) (indicating, for example, that the
`
`state of the art with respect to genetic manipulation techniques was “quite
`
`advanced”).
`
`Patent Owner does not propose an alternative definition. See Prelim.
`
`Resp. 17–20. Patent Owner argues, however, that Petitioners’ attempt to
`
`read into their definition of the level of skill in the art knowledge of
`
`knocking out the gene for “the fucose-adding enzyme fucosyltransferase,”
`
`thereby “resulting in a modified sugar chain, giving improved antibodies,” is
`
`improper and contrary to the evidence. Prelim. Resp. 17.
`
`We agree with Patent Owner to the extent that Petitioner’s proposed
`
`definition attempts to avoid a requirement of proof. More specifically,
`
`Petitioner attempts to sidestep the issue of whether the prior art discloses a
`
`mammalian α1,6-fucosyltransferase gene, or any method of deleting or
`
`adding a mutation to the genomic α1,6-fucosyltransferase gene, as required
`
`by the challenged claims. Genetic manipulation techniques may have been
`
`“quite advanced,” but some credible evidence that the FUT8 gene was
`
`known is necessary.
`
`Accordingly, on this record, we adopt only a portion of Petitioner’s
`
`definition of the level of ordinary skill in the art. Specifically – a person of
`
`ordinary skill in the art would have had a doctorate level degree in a field
`
`concerned with molecular immunology or biochemistry of glycoproteins
`
`including antibodies, knowledge of routine generic genetic procedures
`
`13
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`including gene knock-outs, and a few years practical experience working on
`
`the genetics of antibodies.
`
`We further note that the prior art itself demonstrates this level of skill
`
`in the art at the time of the invention. See Okajima v. Bourdeau, 261 F.3d
`
`1350, 1355 (Fed. Cir. 2001) (explaining that specific findings regarding
`
`ordinary skill level are not required “where the prior art itself reflects an
`
`appropriate level and a need for testimony is not shown” (quoting Litton
`
`Indus. Prods., Inc. v. Solid State Sys. Corp., 755 F.2d 158, 163 (Fed. Cir.
`
`1985)).
`
`C.
`
`Asserted Grounds
`
`We next turn to the six grounds of invalidity asserted in the Petition:
`
`whether the subject matter of claims 1–6 of the ’466 Patent would have been
`
`obviousness to a person of ordinary skill in the art at the time of the
`
`invention over Rothman or Harris in view of Umaña and the knowledge of a
`
`person of ordinary skill in the art (Grounds 1 and 2); Umaña and Malý and
`
`the knowledge of a person of ordinary skill in the art (Grounds 3 and 4) or,
`
`in the case of claim 5 alone, Umaña and Gao and the knowledge of a person
`
`of ordinary skill in the art (Grounds 5 and 6). Pet. 20.
`
`Briefly, Petitioner contends that Rothman and Harris each suggest a
`
`link between removal of fucose and improved ADCC—and thus motivation
`
`to generate IgG-type antibodies cells lacking α1,6-fucosyltransferase
`
`activity—, whereas “Umaña, teaches the creation of mammalian host cells
`
`with modified sugar-adding genes (including ‘knock-outs’) to create sugar-
`
`modified antibodies with more efficient ADCC” properties.” Pet. 21–53.
`
`According to Petitioner, “[t]he necessary steps for creating such a host
`
`14
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`cell. . . were in the common knowledge.” Id. 21–22 (citing Ex. 1007 ¶¶ 32–
`
`34, 39–42, 60–75).
`
`With respect to Grounds 3 and 4, Petitioner further argues that one of
`
`ordinary skill in the art would have been motivated by the teachings of
`
`Rothman to obtain host cells that had decreased or no α1,6-
`
`fucosyltransferase activity and “emboldened . . . to pursue ‘knock-out’ of
`
`α1,6-fucosyltransferase” by Malý’s “knockout of the gene for α(1,3)-
`
`fucosyltransferase in mouse embryos.” Id. 35–50.13
`
`Patent Owner responds that the challenged claims are not obvious
`
`because none of the cited references disclose “decreased or no α1,6-
`
`fucosyltransferase activity,” the “gene encoding fucosyltransferase,” and
`
`“deleting . . . or . . . adding a mutation” to such a gene. Prelim. Resp. 27–38.
`
`We address the dispositive issue below.
`
`i. Grounds 1 – 6 and “Common Knowledge”
`
`Common knowledge is a component of each of Grounds 1–6. Pet. 20.
`
`We address only Ground 1 to illustrate the deficiency of the asserted
`
`“common knowledge,” but note that grounds 2–6 fail for the same reason.
`
`In Ground 1, Petitioner asserts that Umaña teaches the creation of
`
`mammalian host cells with modified sugar adding genes (including “knock-
`
`outs”) to create sugar-modified antibodies with more efficient ADCC. Pet.
`
`21, citing Ex. 1004 generally. Petitioner relies on Rothman as teaching the
`
`correlation between a no-fucose sugar-chain structure and enhanced
`
`antibody function ADCC. More specifically, Petitioner cites the reference’s
`
`
`
`13 Petitioner further references Gao, in Grounds 5 and 6, to highlight the
`applicability of cell line YB2/0 for production of IgG-secreting hybridomas.
`Id. 50–53.
`
`15
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`conclusion that the “absence of core fucosylation itself would appear to be a
`
`likely candidate as a structural feature necessary for enhancement of NK
`
`cell-mediated ADCC.” Id., citing Ex. 1002 at 1122. Accordingly, Petitioner
`
`reasons that Rothman provides motivation to target the α1,6-
`
`fucosyltransferase gene for genetic knockout. Pet. 21. The “necessary steps
`
`for creating a host cell with a knocked out gene for the enzyme that adds
`
`fucose to the sugar chain” are said to be in the “common knowledge.” Pet.
`
`21, citing Ex. 1007, ¶¶ 32–34, 39–42, 65–81, which is the testimony of Dr.
`
`Van Ness.
`
`Patent Owner, on the other hand, asserts that the Petition fails to point
`
`out where key claim elements can be found in the prior art. Prelim. Resp.
`
`25. More specifically, Patent Owner asserts that claims 1–6 contain a
`
`critical element of the gene encoding α1,6-fucosyltransferase, which is either
`
`deleted or has a mutation added to it resulting in the claimed mammalian
`
`host cell with reduced or eliminated α1,6-fucosyltransferase activity. Id.
`
`According to the Patent Owner, none of the references contain any
`
`identification of this gene, and the absence of identification of the gene is
`
`fatal to the Petition. Id. 26.
`
`We agree with Patent Owner.
`
`The claims of the ’446 Patent are directed to an isolated “mammalian
`
`host cell which has decreased or no α1,6-fucosyltransferase activity.” See
`
`Ex. 1001, 183:30–31. This decreased activity is by virtue of a modification
`
`to the gene encoding α1,6-fucosyltransferase, the enzyme which permits
`
`fucose to be added to the sugar chain. Citing paragraphs 39–41 of Dr. Van
`
`Ness’s Declaration, Petitioner asserts that “[t]he human fucosyltransferase
`
`gene sequence was cloned in 1994.” Pet. 7 (emphasis added). In support of
`
`16
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`Petitioner’s assertion, Dr. Van Ness testifies that “[t]he human
`
`fucosyltransferase gene sequence had been cloned in 1994 by Sasaki et
`
`al.(269(20) J. BIOL. CHEM. 14730–37 (1994)).” Ex. 1007 ¶ 40 (emphasis
`
`added).
`
`This is the heart of the evidence supporting “common knowledge” in
`
`each of Grounds 1–6. However, no copy of the evidence cited was provided
`
`as an exhibit by Petitioner. Exhibit 2009, a copy of Sasaki, was in fact
`
`supplied by the Patent Owner in its Preliminary Response.
`
`After careful review of the evidence of record, we find it to be
`
`contrary to the assertion of Dr. Van Ness.
`
`First, claim 1 recites α1,6-fucosyltransferase. Our review of Sasaki
`
`fails to turn up mention of α1,6-fucosyltransferase, but instead we find it
`
`discloses the cloning of Fuc-TVII, a member of “a unique class of the α1,3-
`
`fucosyltransferase family.” Ex. 2009, 14730. Malý discloses that there are
`
`five human fucosyltransferase genes encoding α1,3-fucosyltransferases
`
`alone. Ex. 1005, 649. Dr. Van Ness’s statement glosses over these facts.
`
`Petitioner presents no persuasive evidence suggesting that the
`
`nucleotide sequence of any α1,3-fucosyltransferase is related to that of the
`
`α1,6-fucosyltransferase recited in claim 1. Moreover, Petitioner does not
`
`establish that any of the α1,3-fucosyltransferases are involved in the
`
`fucosylation of antibodies. See Ex. 1038 98:17–20 (Dr. Van Ness admitting
`
`that he is “not aware” whether “α1,3-fucosyltransferases are involved in
`
`adding fucose to the complex sugar chain in antibodies”); Prelim. Resp. 36.
`
`Petitioner alternatively contends in support of its position that during
`
`prosecution, Patent Owner admitted “that the gene sequence for α(1,6)-
`
`fucosyltransferase had already been published.” Pet. 7 (citing Ex. 1036,
`
`17
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`Aug. 12, 2004 Amendment at 33–34). Asserting that the genetic sequence
`
`of α1,6-fucosyltransferase was “known,” Petitioner’s witness Dr. Van Ness
`
`further testifies that “a POSA could have determined [the sequence of α1,6-
`
`fucosyltransferase] independently and routinely.” Ex. 1007 ¶¶ 41, 68.
`
`Dr. Van Ness’s evidentiary support for this positon is that “during
`
`prosecution of the ’446 patent’s parent application, the patentee cited
`
`specific prior-art articles that confirm that sufficient information of the gene
`
`sequence for α1,6-fucosyltransferase had already been published” (id. ¶ 40
`
`(citing Ex. 1036, Aug. 12, 2004 Amendment at 33–34)). These assertions
`
`are not supported by the evidence in the record before us.
`
`According to the Specification, the inventors of the ’446 Patent cloned
`
`Exon 2 of the FUT 8 genomic sequence using a cDNA probe, and used that
`
`DNA to create a genomic knockout of α1,6-fucosyltransferase in
`
`mammalian cells. See Ex. 1001, 99:3–111:46.
`
`In responding to a lack of enablement rejection under § 112, first
`
`paragraph, Applicants argued that “one of ordinary skill in the art would
`
`have been able to prepare a cell in which the enzyme activity of α1,6-
`
`fucosyltransferase . . . is deleted or decreased without limitation to the exon
`
`2, based on the present specification.” Ex. 1036, Aug. 12, 2004 Amendment
`
`at 33 (emphasis added). Applicants additionally asserted that, “[o]ne of
`
`ordinary skill in the art would appreciate the intron and exon structures of . .
`
`. α1,6-fucosyltransferase[] by using a method similar to the method
`
`described in Example 12 of the present specification if the cDNA of the
`
`target gene is known.” Id. 33–34 (emphasis added).
`
`Thus, contrary to Petitioner’s argument, Applicants did not admit that
`
`the genetic sequence of α1,6-fucosyltransferase was known or published, but
`
`18
`
`
`
`IPR2017-01262
`Patent 7,425,446 B2
`
`
`
`that the intron/exon structure of the gene could be determined based upon
`
`knowledge of the FUT8 cDNA disclosed in Example 12 of their
`
`Specification. On the present record, Petitioner fails to establish with
`
`persuasive evidence that DNA encoding any portion of the FUT8 gene was
`
`in the prior art.
`
`Because knowledge of at least some portion of this sequence is
`
`necessary for “deleting a gene encoding α1,6-fucosyltransferase or by
`
`adding a mutation to said gene to reduce or eliminate the α1,6-
`
`fucosyltransferase activity” as set forth in claim 1, we find unsupported
`
`Petitioner’s blanket assertion that “all limitations of claim 1 are taught by
`
`Rothman and Umaña,” with or without the “common knowledge” of one of
`
`ordinary skill in the art. See Pet. 22.
`
`With respect to his testimony that the Applicants “cited specific prior-
`
`art articles that confirm that sufficient information of the gene sequence for
`
`α1,6-fucosyltransferase had already been published,” Dr. Van Ness relies on
`
`Applicants’ statement that:
`
`In reference (i), the structure motif which is important to the
`activity of the fucosyltransferase was expected from
`fucosyltransferases derived from various species (see Figs. 2, 3,
`4 and 6). In the reference (ii), the structure which is important
`to the activity of the fucosyltransferase was similarly expected
`(Fig. 3).
`
`Ex. 1007 ¶ 40 (quoting Ex. 1036, Aug. 12, 2004 Amendment at 34). As